Nurix Therapeutics (NRIX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$701.9M

Revenue (quarter)

$673.1M

Revenue growth (year over year)

+8426.27%

Gross profit (trailing twelve months)

$701.9M

Gross margin

100.00%

Net income (trailing twelve months)

$294.9M

Net income (quarter)

$549.8M

Net income growth (year over year)

+736.20%

Net margin

42.01%

Return on equity

43.99%

EPS (trailing twelve months)

$2.53

Book value per share

$8.87

P/E (trailing twelve months)

9.24

Price to book

2.81

Debt to assets

18.99%

Payout ratio

—

Dividend yield

—

Company profile

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

• Is Nurix Therapeutics (NRIX) profitable?

  Yes. Nurix Therapeutics earned $294.9M in net income over the trailing twelve months, a net margin of 42.01%.

• How much revenue does Nurix Therapeutics (NRIX) make?

  Nurix Therapeutics generated $701.9M in revenue over the trailing twelve months, up 8426.27% year over year.

• What is NRIX's P/E ratio?

  Nurix Therapeutics trades at 9.2 times trailing twelve-month earnings, on an EPS of $2.53.

• How do I buy stock in Nurix Therapeutics (NRIX)?

  NRIX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.